Target-matched therapies in patients with advanced cervical cancers harboring PIK3CA mutations and/or PTEN loss.

被引：0
|
作者：
Hou, Ming-Mo [1 ]
Liu, Xiaochun [1 ]
Piha-Paul, Sarina A. [1 ]
Janku, Filip [1 ]
Wheler, Jennifer [1 ]
Naing, Aung [1 ]
Bodurka, Diane [1 ]
Schmeler, Kathleen [1 ]
Lu, Karen [1 ]
Zinner, Ralph [1 ]
Hong, David [1 ]
Meric-Bernstam, Funda [1 ]
Kurzrock, Razelle [2 ]
Fu, Siqing [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] UC San Diego Moores Canc Ctr, La Jolla, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-B191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B191
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancers
    Hao, Yujun
    Samuels, Yardena
    Li, Qingling
    Krokowski, Dawid
    Brunengraber, Henri
    Hatzoglou, Maria
    Zhang, Guo-Fang
    Vogelstein, Bert
    Wang, Zhenghe
    CANCER RESEARCH, 2015, 75
  • [42] PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review
    Pergialiotis, Vasilios
    Nikolaou, Christina
    Haidopoulos, Dimitrios
    Frountzas, Maximos
    Thomakos, Nikolaos
    Bellos, Ioannis
    Papapanagiotou, Angeliki
    Rodolakis, Alexandros
    ACTA CYTOLOGICA, 2020, 64 (06) : 547 - 555
  • [43] High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
    Oda, K
    Stokoe, D
    Taketani, Y
    McCormick, F
    CANCER RESEARCH, 2005, 65 (23) : 10669 - 10673
  • [44] Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations
    Ogasawara, A.
    Hihara, T.
    Yabuno, A.
    Shimoyokkaichi, S.
    Shintani, D.
    Ikeda, Y.
    Tai, K.
    Fujiwara, K.
    Watanabe, K.
    Hasegawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Evaluation a Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
    Ogasawara, Aiko
    Hihara, Taro
    Shintani, Daisuke
    Yabuno, Akira
    Ikeda, Yuji
    Tai, Kenji
    Fujiwara, Keiichi
    Watanabe, Keisuke
    Hasegawa, Kosei
    CANCER RESEARCH AND TREATMENT, 2020, 52 (04): : 1219 - 1228
  • [46] Concordant analysis of KRAS, BRAF, PIK3CA mutations and PTEN expression between primary colorectal cancer and matched metastases
    Chen Mao
    Xin-Yin Wu
    Zu-Yao Yang
    Diane Erin Threapleton
    Jin-Qiu Yuan
    Yuan-Yuan Yu
    Jin-Ling Tang
    Scientific Reports, 5
  • [47] Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases
    Mao, Chen
    Wu, Xin-Yin
    Yang, Zu-Yao
    Threapleton, Diane Erin
    Yuan, Jin-Qiu
    Yu, Yuan-Yuan
    Tang, Jin-Ling
    SCIENTIFIC REPORTS, 2015, 5 : 8065
  • [48] Oncogenic activation of PIK3CA in cancers: Emerging targeted therapies in precision oncology
    Wang, Yuxiang
    Rozen, Valery
    Zhao, Yiqing
    Wang, Zhenghe
    GENES & DISEASES, 2025, 12 (02)
  • [49] PIK3CA mutations in Tunisian patients with metastatic colorectal cancer: Patient stratification for targeted therapies
    Jaballah-Gabteni, A.
    Tounsi, H. Guettiti
    Ben Ayed, I.
    Yaiche, H.
    Ben Jemii, N.
    Wider, D.
    Boubaker, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S350 - S350
  • [50] Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
    Xing, Yan
    Lin, Nancy U.
    Maurer, Matthew A.
    Chen, Huiqin
    Mahvash, Armeen
    Sahin, Aysegul
    Akcakanat, Argun
    Li, Yisheng
    Abramson, Vandana
    Litton, Jennifer
    Chavez-MacGregor, Mariana
    Valero, Vicente
    Piha-Paul, Sarina A.
    Hong, David
    Do, Kim-Anh
    Tarco, Emily
    Riall, Dianna
    Eterovic, Agda Karina
    Wulf, Gerburg M.
    Cantley, Lewis C.
    Mills, Gordon B.
    Doyle, L. Austin
    Winer, Eric
    Hortobagyi, Gabriel N.
    Gonzalez-Angulo, Ana Maria
    Meric-Bernstam, Funda
    BREAST CANCER RESEARCH, 2019, 21 (1):
12345